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Abstract
Background: Previous studies showed that plasma n-3 polyunsaturated fatty acid (PUFA) was negatively associated
with plasma homocysteine (Hcy).
Objective: We investigated the regulatory effect of n-3 PUFA on mRNA expression of the critical genes encoding
the enzymes involved in Hcy metabolism.
Methods: HepG2 cells were treated with docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), alpha-linolenic
acid (ALA) respectively for 48 h. The cells were collected and total RNA was isolated. The mRNA expression levels
of the genes were determined by using Real Time-PCR.
Results: Compared with controls, the mRNA expression levels of 5-methyltetrahydrofolate reductase (MTHFR) were
significantly increased in the DHA group (p < 0.05) and ALA group (p < 0.05); Significantly down-regulated mRNA
expression of methionine adenosyltransferase (MAT) was observed with the treatments compared with the
controls; the level of MAT expression was significant lower in the DHA group than the ALA group (p < 0.05);
Cystathionine-g-lyase (CSE) expression was significantly increased in the DHA (p < 0.05) and EPA groups (p < 0.05)
compared with control. No significant changes were shown in mRNA expression levels of S-adenosylhomocysteine
hydrolases (SAHH), cystathionine b-synthase (CBS), and 5-methyltetrahydrofolate-homocysteine methyltransferase
(MTR).
Conclusions: Our results suggest that DHA up-regulates CSE and MTHFR mRNA expression and down-regulates
MAT mRNA expression involved in Hcy metabolism.
Background
Hyperhomocysteinaemia (HHcy) has been reported to
be an independent risk factor for cardiovascular disease
(CVD) [1]. Homocysteine (Hcy) is a thiol-containing
amino acid derived from methionine metabolism [2]. In
methionine metabolism, methionine is converted to S-
adenosylmethionine (SAM) via methionine adenosyl-
transferase (MAT), which is the only methyl-donating
pathway in humans [3]. S-adenosylhomocysteine (SAH),
a product of this methyl-transferase reaction, is hydro-
lyzed to Hcy in a reversible reaction via the S-adenosyl-
homocysteine hydrolases (SAHH). Once synthesized,
Hcy can be degraded through two enzymatic pathways:
transsulfuration and remethylation (Figure 1) [1]. In
remethylation, Hcy can be converted back to methionine
in the remethylation pathway via 5-methyltetrahydrofo-
late reductase (MTHFR) and methionine synthase (MS)
using cofactors such as vitamin B12 and folic acid [4]. In
the transsulfuration pathway, Hcy is condensed with ser-
ine to form cystathionine via vitamin B6 dependent
cystathionine b-synthase (CBS), subsequently, cystathio-
nine is converted to cysteine, a-ketosuccinic acid, taur-
ine, and hydrogen sulfide (H2S) via vitamin B6
dependent cystathionine-g-lyase (CSE) [5].
Variations in the levels of Hcy can be due to defects
of the genes encoding the critical enzymes involved in
methionine metabolism [6], nutritional status for folic
acid, vitamin B6 and B12,a n dv a r i o u sp e r s o n a l
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any medium, provided the original work is properly cited.behaviours like physical inactivity and smoking [7]. Hcy
metabolism is nutritionally regulated in part through the
utilization of Hcy in the transsulfuration and remethyla-
tion pathways [8].
N-3 polyunsaturated fatty acids (PUFA) have protec-
tive effects on the cardiovascular system. Dietary intake
of fish oil rich in n-3 PUFA leads to increased levels of
n-3 PUFA in tissues [9], which is associated with
reduced incidence of cardiovascular events via regula-
tory effects on blood pressure [10], serum/plasma tria-
cylglycerol (TG) levels [11], antithrombotic effects and
heart rate variability [12].
In a previous study, we reported that plasma Hcy was
also significantly and negatively correlated with plasma
phospholipids (PL) 22:6n-3 (DHA), total n-3 PUFA and n-
3/n-6 PUFA in healthy Australian men [13], and in middle
aged and geriatric hyperlipaemic patients in Hangzhou
[14]. In our cross sectional study, MAT1A genotypes were
found to interact with dietary PUFA in determining plasma
Hcy [8]. Furthermore, intervention studies and our recent
meta-analysis document that the high consumption of n-3
PUFA decreases plasma Hcy [15]. However, the mechan-
isms which may explain the relationship between n-3
PUFA and plasma Hcy levels are not yet fully understood.
In a previous report we suggested that a possible mechan-
ism for this relationship is that n-3 PUFA, especially 22:6n-
3, may modulate gene expression of an enzyme involved in
the formation and metabolism of plasma Hcy [13].
Furthermore, in mammals, two genes (MAT1A and
MAT2A), play an important role in human hepatocellular
carcinoma, through facilitation of cancer cell growth [16].
In addition, SAH and Hcy is associated with invasion
activities of hepatoma cells, increased level of plasma Hcy
is a reflection of the degree of liver injury is more sensitive
biochemical indicator of liver cirrhosis and liver cancer
[17]. Therefore, to investigate the potential mechanism by
which n-3 PUFA decrease Hcy in HepG-2 cell line, we
conducted the cell culture to examine the nutritional regu-
lation of n-3 PUFA (22:6n-3, DHA; 20:5n-3, EPA; 18:3n-3,
ALA) on the mRNA expression of the genes encoding the
key enzymes involved in Hcy metabolism.
Methods
Cell Culture
HepG-2 cell was purchased from Chinese Academy of
Science. HepG-2 was cultured in DMEM medium
(Inalco, USA) supplemented with 10% fetal bovine
serum at 37°C in a humidified atmosphere of 5% CO2.
Cells were seeded in 25-cm
2 cell culture flasks or in 12-
wells plastic plate (Corning, USA), and grown to 50-70%
confluence.
Treatment of fatty acid on HepG2 cells
Prior to experiments, cells were washed twice with
p h o s p h a t eb u f f e r e ds a l i n e( PBS) and once with serum-
free DMEM medium without antibiotics. One milliliter
containing 1 × 10
5 HepG2 cells was added into each
well of the 12-wells plastic plate. For fatty acid treat-
ment, the fatty acids were dissolved in ethanol [18].
After incubation at 37°C for 24 h, the treatment groups
were added with fresh culture media with a final fatty
acids concentration (DHA, EPA, ALA, Cayman, USA) of
150 μM [19], Controls were exposed to an equal con-
centration of ethanol to that in the fatty acid exposed
samples. After the treatment with the fatty acids for 48
h, the cells were collected for further experiments. Total
RNA was extracted with Trizol reagent (Shinegene,
China) as described by Zhang et al [20]. RNA was quan-
tified with Nanodrop (Peqlab, Erlangen, Germany) and
the RNA integrity number (RIN) was measured with
Bioanalyzer (Agilent, Böblingen, Germany). No RNA
was used with a RIN below 8.5. All experiments were
performed in triplicate and repeated at least three times.
Assay of the fatty acid composition in HepG2 cell
membrane
The cell was collected and centrifuged at 800 rcf. Total
lipid content of cell membrane was extracted with
chloroform/methanol solution (2:1, vol/vol) containing
50 mg/L butylated hydroxytoluene (Tokyo Kasei Kogyo
Co., Ltd., Tokyo, Japan)., The PL fraction was separated
by thin layer chromatography (TLC). The PL fatty acids
were converted to methyl ester by using 2 mL of 2%
H2SO4-methanol for 2 hours at 70°C. The fatty acid
Figure 1 The diagram shows the enzyme points (in cycle) on
which the effects of n-3 PUFA might operate in the
homocysteine metabolic pathway of relevance. The critical
genes in cycle were determined in present study. MTR: 5-
methyltetrahydrofolate-homocysteine methyltransferase; MAT:
methionine adenosyl transferase; SAHH: S-adenosylhomocysteine
hydrolases; CBS: Cystathionine b-synthase; CSE: Cystathionine g-lyase;
MTHFR: Methylenetetrahydrafolate reductase; BHMT: Betaine-
homocysteine methyltransferase; DMG: Dimethylglycine; 5, 10-CH3-
THF: 5, 10-Methylene-Tetrahydrofolate; 5-CH3-THF: 5-Methyl-
Tetrahydrofolate; THF: Tetrahydrofolate; SHMT: Serine hydroxymethyl
transferase; Pi: Orthophosphate; PPi: Pyrophosphate.
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chromatography as described previously [21].
Assay of mRNA expression of the critical genes involved
in methionine metabolism
Real-time polymerase chain reaction
Total RNA from ethanol or n-3 PUFA treated HepG2
cells were extracted by using the Trizol reagent (Shin-
gene, Shanghai, China). The mRNA concentration and
mRNA quality were determined by using the NanoDrop
ND-2000. A value of 260/280 ratio (1.8-2.0) indicates
that the RNA is pure. The first strand cDNA was
synthesized using cDNA sythesis kit (shinegene, Shang-
hai, China), the Real Time-PCR was conducted on iCy-
cler PCR using the HotStart DNA Master SYBR Green I
kit (Takara, Dalian, China) [22]. The primers used for
the variety genes studied are shown in Table 1. All PCR
tests were carried out in duplicate with a final volume
of 20 μL containing cDNA. The thermal cycling condi-
tions used were as follows: an initial DNA denaturation
step at 95°C for 5 seconds, followed by 40 cycles of
denaturation at 95°C for 5 seconds, primer annealing at
optimal temperature for 20 s, extension at 72°C for 30 s,
and an additional incubation step at 80-85°C for 30 s to
measure SYBR Green I fluorescence. Finally, melt curve
analysis was performed by slowly cooling the PCR from
95 to 60°C (0.5°C per cycle) with simultaneous measure-
ment of the SYBR Green I signal intensity.
The quantification of Real Time-PCR
Gene expression was quantitated by using the compara-
tive C (t) method [23].
C (t), the threshold cycle, is the number of cycles it
takes for a sample to reach the level where the rate of
amplification is the greatest during the exponential
phase.
The quantification is used to determine the ratio
between the quantity of a target molecule in a sample
and in the calibrator (calibrator being e.g. untreated
cell). The most common application of this method is
the analysis of gene expression, e.g. comparisons of gene
expression levels in different samples. Target molecule
quantity is usually normalized with a housekeeping
gene. Comparative C (t) method can be used for relative
quantification. Both the sample and calibrator data is
first normalized against variation in sample quality and
quantity. Normalized values, C (t) s, are first calculated
from following equations:
 C (t)sample =C (t)target − (t)housekeeping gene
 C (t)calibrator =C (t)target − (t)housekeeping gene
The ΔΔC is then determined using the following for-
mula:
  C (t) =  C (t)sample −  C(t)calibrator
Expression of the target gene normalized to the house-
keeping gene and relative to the calibrator = 2
-ΔΔC (t).
Statistical analysis
The data analyses were performed using an SPSS ver-
sion 12 (SPSS Inc, Chicago, IL, USA) software program.
All data are expressed as mean ± SD. Statistical analysis
was performed using post hoc tests in ANOVA; Differ-
ences between treatments were considered to be statisti-
cally significant at p < 0.05.
Results
The phospholipids fatty acid composition of cell
membrane of HepG2 cell after the treatment of n-3 PUFA
When compared with the control group, the concentra-
tion of 22:6n-3, 20:5n-3, 18:3n-3 were significantly
increased in the three treated groups respectively (p <
0.05); the level of n-3 PUFA was also significantly ele-
vated in the three groups (p < 0.05) (Table 2).
The mRNA expression of genes encoding the critical
enzymes involved in methionine metabolism in HepG2
cell was determined by Real Time-PCR after the treatment
of n-3 PUFA
The expression levels of MTHFR were significantly
increased in the DHA group (p < 0.05) and the ALA
group (p < 0.05) when compared with control (Figure 2A);
Significantly decreased expression of MAT was
observed in the three groups compared with control;





MAT NM_013283 F: 5’- ACTTTGTTCCCGGGAGCTGTC -3’
R: 5’- AACTGCATGCCAATTATTCTGCTG -3’
SAHH NM_000687 F: 5’- CACCACAGGCTGTATTGACATCATC -3’
R: 5’- GTCCAATGTTACACACAATGGCATC -3’
MTR NM_000254 F: 5’-TAAGATTTGCAAAGGTTGGGTCTGA-3’
R: 5’-CTGGACATACAGGTGGGAGTTGG-3’
MTHFR NM_005957 F: 5’- TGTGTGAATTCTGCAACTAGCCAAG -3’
R: 5’- ATGAGCCACCACACCTGCTG -3’
CSE NM_153742 F: 5’-CCTTTGGCTCTGGGAGCTGATA-3’
R: 5’-ATTAACAGACACCAGGCCCATTACA-3’
CBS NM_000071 F: 5’-TGTGGGCACACCATCGAGA-3’
R: 5’-AGCGTCACCATTCCCAGGATTA-3’
b-actin NM_001101 F: 5’- CGACAACGGCTCCGGCATGT-3’
R: 5’- TGGGCCTCGTCGCCCACATA-3’
MAT: methionine adenosyltransferase; SAHH: S-adenosylhomocysteine
hydrolase; MTR: 5-methyltetrahydrofolate-homocysteine methyltransferase;
MTHFR: 5, 10-methylenetetrahydrofolate reductase; CSE: cystathionine g-lyase;
CBS: cystathionine b-synthase; b-action: housekeeping gene
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cant lower in the DHA group than the ALA group (p <
0.05) (Figure 2B).
CSE expression was significantly increased in the DHA
(p < 0.05) and EPA groups (p < 0.05) compared with
control (Figure 2C).
No significant changes were seen in expression levels
of SAHH, CBS, and MTR between the four groups (Fig-
ure 2D, E, F).
Discussion
The objective of the present study was to investigate the
regulatory effect of n-3 PUFA on mRNA expression of
the genes encoding the critical enzymes involved in
methionine metabolism.
We observed that n-3 PUFA up-regulates CSE and
MTHFR mRNA expression and down-regulate MAT
mRNA expression involved in Hcy metabolism. We sug-
gest that this regulatory effect on gene expression is
associated with decreased Hcy concentration.
A higher consumption of fish oil rich in n-3 PUFA is
associated with reduced risk of cardiovascular events.
Our previous studies have indicated that increased
22:6n-3 and n-3/n-6 PUFA in platelet and plasma PL is
associated with decreased plasma Hcy [13,14]. Further-
more, meta-analysis confirms that n-3 PUFA decrease
plasma Hcy [15]. In a previous animal study we have
also demonstrated that 8 weeks of tuna oil treatment
significantly decreases the plasma Hcy concentration in
rats [24]. Yet HHcy is caused partly by genetic factors,
including polymorphisms of genes encoding enzymes
involved in Hcy metabolism, such as MTHFR, MTR,
MTRR, and CBS [25,26]. A common mutation in
MTHFR, MAT, and MTR results in a thermolabile var-
iant with reduced activity [27,28]. Regulation of the gene
expression of these critical genes using nutrients could
make beneficial their coded enzyme activity.
To explain why n-3 PUFA decreases the level of Hcy,
we examined the effect of n-3 PUFA on the mRNA
expression of genes encoding the critical enzymes
involved in methionine metabolism. In the present
study, n-3 PUFA has been successfully incorporated into
phospholipids of HepG2 cell membranes. Over the past
10 years, it has become evident that n-3 PUFA have a
wide range of functions and are essential components of
cells to maintain various functions and organelle struc-
tures, They can act as signaling molecules to regulate
gene expression, encoding proteins forroles in fatty acid
transport or metabolism, and act in differentiation,
growth and metabolism [29,30]. Therefore, it is not sur-
prising that the changes in PL fatty acid composition of
cell membrane affected in the present studies can
account for changes in mRNA expression of the critical
genes involved in methionine metabolism, albeit with
some selectivity.
We found that mRNA expression of MAT was signifi-
cantly down-regulated by n-3PUFA. Thus, n-3 PUFA
can affect the rate of SAM synthesis based on the activ-
ity of MAT. The intracellular SAM concentration is an
important determinant of the fate of Hcy molecules [5].
But the resultant decrease in SAM synthesis via MAT
would not stimulate SAH production which will be cata-
lyzed to Hcy. The lack of recognizable change in SAHH
expression presumably helps avoid an increase in Hcy,
because the hydrolysis of SAH by the enzyme SAHH
has been shown to be the sole intracellular source of
Hcy [31]. SAHH expression was unchanged with n-3
PUFA when compared with control. Therefore, a
decrease in SAH synthesis resulting from a decreased
level of SAM would contribute to a reduction of Hcy
formation.
SAM concentration plays an important role in the fate
of Hcy molecules [5]. The potential mechanism is that
SAM acts as not only as an allosteric inhibitor of
MTHFR, but also an activator of CBS [32,33]. As such
an effector, SAM suppresses the synthesis of N-5-
methyltetrahydrofolate which is an important substrate
required for remethylation and promotes the initial
reaction of transsulfuration (CBS). Hcy, when synthe-
sized, acquires a methyl group from N-5-methyltetrahy-
drofolate or from betaine to form methionine via
vitamin B12 dependent MTHFR and MTR respectively
in the remethylation pathway [5]. The impairment of
the remethylation pathway due to an inadequate status
of either folate or vitaminB12 or to defects in the gene
encoding for MTHFR will lead to a substantial increase
in plasma Hcy concentration [34,35]. In the present
study, the MTR expression was not significantly
affected. However, MAT was down-regulated by DHA,
Table 2 The fatty acid composition of cell membrane of
HepG2 cell (%).
Fatty acid Control DHA EPA ALA
Total SFA 7.5 ± 1.1 7.5 ± 1.0 7.8 ± 1.2 7.6 ± 1.0
Total MUFA 75.3 ± 2.7 75.3 ± 3.1 74.5 ± 3.8 74.2 ± 2.9
Total n-6 PUFA 13.4 ± 1.3 12.5 ± 1.9 13.4 ± 2.0 13.4 ± 1.9
18:3n-3 1.3 ± 0.1
b 1.3 ± 0.4
b 1.5 ± 0.2
b 2.4 ± 0.1
a
20:5n-3 1.3 ± 0.2
b 1.3 ± 0.1
b 1.6 ± 0.4
a 1.4 ± 0.0
b
22:5n-3 0.4 ± 0.0 0.4 ± 0.2 0.5 ± 0.1 0.5 ± 0.0
22:6n-3 0.8 ± 0.2
b 1.7 ± 1.0
a 0.7 ± 0.1
b 0.8 ± 0.3
b
Total n-3 PUFA 3.8 ± 1.2
b 4.7 ± 1.7
a 4.3 ± 1.2
a 5.1 ± 0.9
a
The data was presented as Mean ± SD.
a, b, c Values within one row with different letters are significantly different (p
< 0.5).
SFA: saturated fatty acid. MUFA: monounsaturated fatty acid. PUFA:
polyunsaturated fatty acid. DHA: docosahexaenoic acid. EPA: eicosapentaenoic
acid. ALA: alpha-linolenic acid.
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when compared with control. Therefore, the decreased
SAM concentration is insufficient for the inhibition of
MTHFR; the result is an increased rate of N-5-methylte-
trahydrofolate synthesis and Hcy remethylation [5],
thereby reducing the level of Hcy.
In the transsulfuration pathway, Hcy condenses with
serine to form cystathionine via CBS (using vitamin B6
as cofactor). Impairment in the transsulfuration pathway
due to heterozygous defects in the CBS gene or inade-
quate levels of vitamin B6 will lead to a very slight
increase in fasting plasma Hcy levels [36,37]. CBS and
CSE are the most important determinants in the trans-
sulfuration pathway. The present study did not show a
significant effect of n-3 PUFA on mRNA expression of
CBS, However, the CSE mRNA expression was signifi-
cantly up-regulated by DHA and EPA. CSE, which is a
vitamin B6 dependent enzyme, catalyzes the conversion
of cystathionine into cysteine, a-ketobutyrate, taurine
and H2S and is the rate-limiting enzyme for the synth-
esis of cysteine from Hcy [38]. In a previous study, we
also found that the enzyme activity and mRNA
Figure 2 The mRNA expression of genes in methionine metabolism in HepG-2 cell as determined by Real Time-PCR.a ,b ,cV a l u e s
within the four bars with different letters are significantly different (p < 0.5) (n = 9).
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tuna oil supplementation [24]. Thus up-regulated CSE
mRNA expression expedited the degradation of
cystathionine. This means that the transsulfuration reac-
tion will move in a direction beneficial for a decrease in
Hcy. Recently, elevated H2S has been proposed as a new
gasotransmitter in the modulation of cardiovascular
function [39,40]. Hcy-H2S metabolic imbalance could be
an important mechanism in the pathogenesis of hyper-
tension [40]. The up-regulated endogenous H2S/CSE
pathway in pulmonary arteries by l-arginine is involved
in the mechanisms by which l-arginine influences pul-
monary hypertension [41]. The present findings also
suggest that n-3 PUFA may ameliorate hypertension by
decreasing Hcy as well as by increasing H2Sa sar e s u l t
of up-regulated CSE gene expression.
The potential mechanisms by which n-3 PUFA regulate
CSE, MAT, and MTHFR gene expression are not clear.
Previous studies have demonstrated that n-3 PUFA gov-
erns oxidative gene expression involved in lipid metabo-
lism by activating the transcription factor peroxisome
proliferator-activated receptor (PPAR) alpha. N-3 PUFA
suppress lipogenic gene expression by reducing the
nuclear abundance and DNA-binding affinity of tran-
scription factors responsible for imparting insulin and
carbohydrate control to lipogenic and glycolytic genes. In
particular, n-3 PUFA suppress the nuclear abundance
and expression of sterol regulatory element binding pro-
tein-1 and reduce the DNA-binding activities of nuclear
factor Y, Sp1 and possibly hepatic nuclear factor-4 [30].
Furthermore, Narayanan et al reported that DHA regu-
lates genes and transcription factors in human colon
Table 3 The predicted transcription factors binding to fatty acid-responsive element in the promoter of the gene
involved in Hcy metabolism
Gene GeneID Transcript Factor Name(s) Chrom Start End
MTR 4548 NM_000254 MA0066 PPARG chr1 236,956,831 236,956,850
MTR 4548 NM_000254 MA0061 NF-kappaB chr1 236,958,560 236,958,569
HHCY 191 NM_000687 MA0061 NF-kappaB chr20 32891257 32891266
HHCY 191 NM_000687 M00242 PPARalpha:RXRalpha chr20 32891807 32891826
HHCY 191 NM_000687 M00964 PXR, CAR, LXR, FXR chr20 32892802 32892813
HHCY 191 NM_000687 T00720 RAR-gamma chr20 32891787 32891797
HHCY 191 NM_000687 MA0074 RXRA::VDR chr20 32891381 32891395
CSE 1491 NM_153742 M00774 NF-kappaB chr1 70876211 70876222
CSE 1491 NM_153742 M00762 PPAR, HNF-4, COUP, chr1 70875793 70875805
CSE 1491 NM_153742 M00518 PPARalpha:RXRalpha chr1 70876539 70876552
CSE 1491 NM_153742 MA0065 PPARG::RXRA chr1 70876537 70876553
CSE 1491 NM_153742 MA0074 RXRA::VDR chr1 70875356 70875369
CSE 1491 NM_153742 T01331 RXR-alpha chr1 70876645 70876657
CBS 875 NM_000071 MA0061 NF-kappaB chr21 44496816 44496825
CBS 875 NM_000071 T00694 PPAR-alpha chr21 44496841 44496851
CBS 875 NM_000071 MA0073 RREB1 chr21 44496183 44496202
CBS 875 NM_000071 MA0074 RXRA::VDR chr21 44496362 44496376
CBS 875 NM_000071 T01349 RXR-beta chr21 44496925 44496932
MAT1A 4143 NM_000429 T05257 CAR2:RXR-alpha chr10 82051245 82051257
MAT1A 4143 NM_000429 M00631 FXR/RXR-alpha chr10 82050669 82050682
MAT1A 4143 NM_000429 MA0061 NF-kappaB chr10 82049620 82049629
MAT1A 4143 NM_000429 MA0105 NFKB1 chr10 82049504 82049514
MAT1A 4143 NM_000429 T02529 PPAR-gamma1 chr10 82051368 82051378
MAT1A 4143 NM_000429 MA0074 RXRA::VDR chr10 82050026 82050040
MAT1A 4143 NM_000429 T01331 RXR-alpha chr10 82050924 82050936
MTHFR 4524 NM_005957 MA0066 PPARG chr1 11866220 11866239
MTHFR 4524 NM_005957 T05313 FXR:RXR-alpha chr1 11867028 11867042
MTHFR 4524 NM_005957 M00774 NF-kappaB chr1 11866612 11866623
MTHFR 4524 NM_005957 M00518 PPARalpha:RXRalpha chr1 11867952 11867966
MTHFR 4524 NM_005957 MA0065 PPARG::RXRA chr1 11867331 11867347
MTHFR 4524 NM_005957 T02529 PPAR-gamma1 chr1 11867417 11867427
MTHFR 4524 NM_005957 M00964 PXR, CAR, LXR, FXR chr1 11866787 11866798
The predicted transcription factors (RXR-alpha) binding to n-3 PUFA-RE in the promoter of MTHFR, CSE, and MAT using web based software Mapper: http://
genome.ufl.edu/mapper/.
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nine members of the RNA II polymerases, transcription
co-repressor associated protein and enhancer binding
proteins such as AP2, in addition to changes in the
expression of the zinc finger group of transcription fac-
tors and also altered expression of peroxisome prolifera-
tors (PPAR alpha and gamma) [42]. Based on these data,
we speculate that a cis-acting n-3 PUFA responsive ele-
ment (n-3 PUFA-RE) may be located in the promoter
region of the n-3 PUFA-regulated genes. To alter gene
transcription, a transcription factor (putative n-3 PUFA-
binding protein) could bind to n-3 PUFA-RE and block
or enhance transcription. In regard to this hypothesis, we
found that the predicted transcription factors (RXR-
alpha) bind to n-3 PUFA-RE in the promoter of MTHFR,
CSE, and MAT though use of web based software Map-
per: http://genome.ufl.edu/mapper/ (Table 3). Our
hypothesis warrants further investigation.
Conclusions
N-3 PUFA up-regulates CSE and MTHFR mRNA
expression and down-regulates MAT mRNA expression
involved in Hcy metabolism. This regulatory effect of n-
3P U F Ao nc r i t i c a lg e n ee x p ression is associated with
decreased Hcy concentration. Our findings provide a
basis for verification of mechanisms by which n-3 PUFA
decreases plasma Hcy.
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